Form 4: Enanta Pharma Grants Chief Product Strategy Officer 100K Options

Enanta Pharmaceuticals Inc. has granted its Chief Product Strategy Officer, Tara Lynn Kieffer, 100,000 stock options with an exercise price of $13.66.

Summary

• Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals Inc. (ENTA), was granted 100,000 stock options.
• The stock options have an exercise price of $13.66 per share.
• The transaction date for this grant is November 25, 2025.
• The options will become exercisable quarterly in substantially equal installments over four years from the grant date (November 25, 2025), subject to continued employment.
• The expiration date for these stock options is November 25, 2035.
• Following this transaction, Ms. Kieffer beneficially owns 100,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a standard executive compensation disclosure, which is generally viewed as a positive for aligning management incentives with shareholder value, but it does not inherently signal new operational performance or strategic shifts.

Positives

• The grant of stock options aligns the interests of the Chief Product Strategy Officer with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over four years promotes executive retention and commitment to the company's strategic goals.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shareholders, although this is a standard aspect of equity compensation.

Future Outlook

The granted stock options will become exercisable quarterly in substantially equal installments over four years from November 25, 2025, contingent upon the optionholder's continued employment.

Industry Context

This is a routine disclosure of executive compensation in the biotechnology or pharmaceutical industry, where equity grants are a common component of attracting and retaining key talent.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard practice in the pharmaceutical and biotechnology sectors for executive compensation, aiming to align long-term incentives with company performance.
• The exercise price of $13.66, presumably the market price on the grant date, is typical for at-the-money option grants.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise, but also benefit from aligned executive incentives.
• Employees (specifically the reporting person): Receives a significant equity incentive, enhancing long-term compensation and retention.

Next Steps

• The Chief Product Strategy Officer must maintain continued employment with Enanta Pharmaceuticals Inc. for the stock options to vest according to the quarterly schedule over four years.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Stock Options, Executive Compensation, Insider Transaction, Form 4, Tara Lynn Kieffer, Chief Product Strategy Officer